达拉他韦联合阿舒瑞韦治疗基因1b型慢性丙型肝炎13例报告

冯亦农; 王泽红; 周丽; 石少媛; 王永翔

doi:10.3969/j.issn.1001-5256.2018.12.028

达拉他韦联合阿舒瑞韦治疗基因1b型慢性丙型肝炎13例报告

DOI: 10.3969/j.issn.1001-5256.2018.12.028

太原市第三人民医院肝病一科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 1503
- HTML全文浏览量: 14
- PDF下载量: 330
- 被引次数: 0
出版历程
- 出版日期: 2018-12-20

Daclatasvir hydrochloride combined with asunaprevir for treatment of genotype 1b chronic hepatitis C: A report of 13 cases

摘要

摘要:
<正>据统计[1],我国一般人群中约有560万HCV感染者,感染率为0. 43%;高危人群和高发地区的HCV感染者约1000万例,每年丙型肝炎新发病例数超过20万。作为肝细胞癌的重要原发病之一,慢性丙型肝炎一直以来都是我国严重的疾病负担。直接抗病毒药物(DAAs)的问世开创了丙型肝炎治疗新时代[1],使丙型肝炎的临床治愈成为可能。现笔者报道应用达拉他韦联合阿舒瑞韦治疗13例慢性丙型肝炎患者的效果及安
- 肝炎,丙型,慢性 /
- 达拉他韦 /
- 阿舒瑞韦 /
- 治疗学 /
- 病例报告
- hepatitis C, chronic /
- daclatasvir /
- asunaprevir /
- therapeutics /
- case reports

HTML全文

参考文献(22)

[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[2] RAO H, WEI L, LOPEZ-TALAVERA JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J]. J Gastroenterol Hepatol, 2014, 29 (3) :545-553.

[3] LEE MH, YANG HI, LU SN, et al. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma[J].Int J Cancer, 2014, 135 (5) :1119-1126.

[4] BENNETT H, WASER N, JOHNSTON K, et al. A review of the burden of hepatitis C virus infecion in China, Japan, South Korea and Taiwan[J]. Hepatol Int, 2015, 9 (3) :378-390.

[5] WEI L, ZHANG MX, XU M, et al. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin[J]. J Gastroenterol Hepatol, 2016, 31 (11) :1860-1867.

[6] WEI L, WANG FS, ZHANG MX, et al. Daclatasvir plus asunaprevir in treatment-na6ve patients with hepatitis C virus genotype 1b infection[J]. World J Gastroenterol, 2018, 24 (12) :1361-1372.

[7] PAWLOTSKY JM. Therapeutic implications of hepatitis C virus resistance to antiviral drugs[J]. Therap Adv Gastroenterol, 2009, 2 (4) :205-219.

[8] LOK AS, GARDINER DF, HZODE C, et al. Randomized trial of daclatasvir and asunaprevir with or without Peg IFN/RBV for hepatitis C virus genotype 1 null responders[J]. J Hepatol, 2014, 60 (3) :490-499.

[9] SUZUKI Y, IKEDA K, SUZUKI F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options[J]. J Hepatol, 2013, 58 (4) :655-662.

[10] KUMADA H, SUZUKI F, SUZUKI Y, et al. Randomized comparison of daclatasvir+asunaprevir versus telaprevir+peginterferon/ribavirin in Japanese hepatitis C virus patients[J]. J Gastroenterol Hepatol, 2016, 31 (1) :14-22.

[11] KUMADA H, SUZUKI Y, IKEDA K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection[J]. Hepatology, 2014, 59 (6) :2083-2091.

[12] MANNS M, POL S, JACOBSON IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:A multinational, phase 3, multicohort study[J]. Lancet, 2014, 384 (9954) :1597-1605.

[13] WANG HL, LU X, YANG X, et al. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:Systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2017, 32 (1) :45-52.

[14] MCPHEE F, WEI L, XIE Q, et al. High SVR with DCV+ASV in HCV GT-1b Chinese, Koreans&Taiwanese without baseline NS5A polymorphisms[R]. APASL, 2016, P-0102.

[15] BARTELS DJ, SULLIVAN JC, ZHANG EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment[J]. J Virol, 2013, 87 (3) :1544-1553.

[16] PAWLOTSKY JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens[J]. Gastroenterology, 2016, 151 (1) :70-86.

[17] WU S, KANDA T, NAKAMOTO S, et al. Hepatitis C virus protease inhibitor-resistance mutations:Our experience and review[J].World J Gastroenterol, 2013, 19 (47) :8940-8948.

[18] European Association for Study of Liver. EASL Recommendations on treatment of hepatitis C 2015[J]. Hepatology, 2015, 63 (1) :199-236.

[19] TERRAULT NA, LOK ASF, Mc MAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD2018 hepatitis B guidance[J]. Hepatology, 2018, 67 (4) :1560-1599.

[20] LIU CJ. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection:Resolved and unresolved issues[J]. J Gastroenterol Hepatol, 2014, 29 (1) :26-30.

[21] GUTIRREZ GARCA ML, MANZANO ALONSO ML, FERRER ROSIQUE J, et al. Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents[J]. Rev Esp Enferm Dig, 2018.[Epub ahead of print]

[22] WANG C, JI D, CHEN J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents[J]. Clin Gastroenterol Hepatol, 2017, 15 (1) :132-136.

施引文献

资源附件(0)

访问统计